Multiprofessional Approach in Diabetes Mellitus

July 11, 2021 updated by: Leonardo Paroche de Matos

The Effectiveness of the Multiprofessional Approach in an Educational Group in the Control of Diabetes Mellitus in Patients Using Oral Hypoglycemic Agents From a Basic Health Unit in the City of Guarulhos/ SP: a Randomized Study

OBJECTIVE: to verify the effectiveness of adopting the practice of educational groups in primary care and the multiprofessional role in the control of diabetes mellitus in adults. METHODOLOGY: a randomized clinical study carried out in an educational group at the Basic Health Unit Nova Bonsucesso with six monthly meetings scheduled with 24 patients with type II diabetes mellitus users of oral hypoglycemic agents divided into two subgroups: 12 users in the control group and 12 users in the control group. study (which will receive the interventions of the multidisciplinary team) and will be accompanied by laboratory tests and individual evaluations to verify the effectiveness of the multidisciplinary action in the control of diabetes mellitus.

Study Overview

Detailed Description

INTRODUCTION: diabetes mellitus is highlighted as an obstacle in health equipment because it is a chronic disease and has a high mortality rate. The pathology results in hyperglycemia, disorders or insufficiency of several organs. OBJECTIVE: to verify the effectiveness of adopting the practice of educational groups in primary care and the multidisciplinary role in the control of diabetes mellitus in adults. THEORETICAL BACKGROUND: type II diabetes mellitus (type II DM) is a pathology that represents a high risk for cardiovascular, renal, ophthalmological complications and in several other systems. It is considered a major issue to be controlled by health services, as the high cost of treatments related to the sequelae of type II DM, as well as high rates of hospitalizations and associated therapies have been increasing and decompensating public budgets. Primary care has a fundamental role in preventing the disease and associated complications. METHODOLOGY: randomized clinical study conducted in an educational group at the Basic Health Unit Nova Bonsucesso with six monthly meetings scheduled with 24 patients with type II diabetes mellitus users of oral hypoglycemic agents divided into two subgroups: 12 users in the control group and 12 users in the group study (which will receive the interventions of the multidisciplinary team) and will be accompanied by laboratory tests and individual evaluations to verify the effectiveness of the multidisciplinary performance in the control of diabetes mellitus. RESULTS: the participants are expected to show improvements in the control of the pathology and awareness about the relevance of self-care, facts that will be observed through laboratory data and subsequent multi-professional evaluations.

Study Type

Interventional

Enrollment (Anticipated)

24

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 60 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • 24 on-insulin-dependent type II diabetes patients (users of oral hypoglycemic agents),
  • over 18 years of age,
  • both sexes,
  • with no restrictions on physical exercise (found after medical evaluation)
  • who agreed to participate voluntarily in the study (after signature of the Free and Informed Consent Form)
  • of a specific area of the Family Health Strategy - chosen by the proximity to the Basic Health Unit.

Exclusion Criteria:

  • Patients with associated pathologies: cardiovascular conditions: Congestive Heart Failure,Decompensated Systemic Arterial Hypertension, Sequela of Acute Myocardial Infarction
  • Cancer patients,
  • Respiratory conditions: Chronic Obstructive Pulmonary Disease, Severe asthma and any other disabling lung condition.
  • Endocrine conditions that aggravate diabetes mellitus: Pancreatic pathologies (pancreatitis, pancreatic cysts, obstructions and pancreatic cancer)
  • Patients with impaired vision,
  • Motor or balance disorders,
  • With any special needs (physical or intellectual),
  • With consequences resulting from the evolution of type II diabetes mellitus
  • Users who refused to participate in the research.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
No Intervention: Placebo
The control group will be evaluated in 2 stages: at the beginning and at the end of the study and will be accompanied only with scheduled medical consultations (also simulating the reality of basic health units with a traditional model of care) and the intervention group will undergo evaluations with the multiprofessional team on two occasions (at the beginning and at the end of the study)
Active Comparator: Specific and educational guidelines on pathology care (diabetes mellitus)

Multiprofessional educational guidelines and analysis of the following exams:

  • Periodontal record, bleeding rate on and visible plaque;
  • Body mass index (BMI): weight (kg) divided by height squared (m²);
  • Serum glucose values;
  • Glycated hemoglobin;
  • Blood count: hemoglobin;
  • Urea: male:
  • Creatinine male;
  • Uric acid;
  • Oxalacetic glutamic transaminase;
  • Glutamic pyruvic transaminase;
  • Total cholesterol and fractions: Cholesterol, Non HDL, LDL, VLDL;
  • Triglycerides;
  • Type I urine;
  • Vitamin D3 25OH;
  • Microalbuminuria;
  • Blood pressure: systolic;
  • Abdominal circumference.

Physician: Guidance on pathology, sequelae and treatment, as well as guidance on the importance of medical monitoring.

Dental surgeon: guidance on oral health, demonstration of brushing techniques and daily flossing and periodontal changes resulting from diabetes mellitus.

Nurse: Guidance on pathology prioritizing pathophysiology, self-care and skin care and wound prevention (vascular sequelae).

Nutritionist: nutritional guidelines on diabetes mellitus and healthy eating habits.

Physiotherapist: guidance on prevention of falls and injuries and health promotion.

Physical educator: guidance on the importance of practicing physical activities for general health, encouraging self-care and body awareness and demonstrating basic physical activities that can be performed at home.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
incidence of periodontitis associated with diabetes mellitus
Time Frame: 6 months
Periodontal record: up to 3mm.
6 months
Risk rate for periodontal disease (in %) associated with diabetes mellitus
Time Frame: 6 months
Bleeding rate on and visible plaque: up to 10%;
6 months
Association of glycemic control with changes in body weight (in kg)
Time Frame: 6 months
Body mass index (BMI): weight (kg) divided by height squared (m²);
6 months
Comparison of glycemic control
Time Frame: 6 months
Serum glucose values: 80 to 130mg/ dl
6 months
% of participants at risk for worsening diabetes mellitus
Time Frame: 6 months
Glycated hemoglobin: <7%
6 months
% of participants at risk for anemic diseases
Time Frame: 6 months
Blood count: hemoglobin: male 13-17g/ dl, female: 12 -15g/ dl
6 months
Concentration of participants at risk for developing kidney complications [urea]
Time Frame: 6 months
Urea: male: <40mg/ dl, female: <55mg/ dl
6 months
Concentration of participants at risk of developing kidney failure
Time Frame: 6 months
Creatinine male: 0.7-1.30mg/ dl, female: 0.5- 1.10mg/ dl
6 months
Concentration of participants at risk for the development of kidney stones and worsening of diabetes mellitus
Time Frame: 6 months
Uric acid: male: 3.4- 7.0mg/ dl, female: 2.4- 7.4mg/ dl
6 months
Concentration of participants at risk for the development of liver complications
Time Frame: 6 months
Oxalacetic glutamic transaminase: male: <50U/ L, female: <40U/ L
6 months
Concentration of participants at risk for the development of liver failure associated with diabetes mellitus
Time Frame: 6 months
Glutamic pyruvic transaminase: male: <50U/ L, female: <40U/ L
6 months
Observation of the risk of developing cardiovascular diseases associated with diabetes mellitus
Time Frame: 6 months
Total cholesterol and fractions: Cholesterol: 190mg/ dl, HDL:> 40mg/ dl, Non HDL: <160mg/ dl, LDL: <100mg/ dl, VLDL: 10- 50mg/ dl
6 months
Observation of triglyceride rates and the development of risk for cardiovascular complications associated with diabetes mellitus
Time Frame: 6 months
Triglycerides: <175mg/ dl
6 months
Concentration of participants with renal complications and urinary glucose and protein elimination associated with diabetes mellitus
Time Frame: 6 months
Type I urine: negative proteinuria and glycosuria
6 months
Concentration of participants at increased risk for diabetes complications related to vitamin D deficiency
Time Frame: 6 months
Vitamin D3 25OH: <60y: >20ng/ dl, >60y: >30ng/dl
6 months
Observation of the risk of developing nephropathies, retinopathies and cardiovascular diseases associated with diabetes mellitus
Time Frame: 6 months
Microalbuminuria: <30mg/day
6 months
Concentration of participants at risk of developing systemic arterial hypertension associated with diabetes mellitus
Time Frame: 6 months
Blood pressure: systolic- <130mmHg, diastolic: <85mHg
6 months
Concentration of participants at increased risk for diabetes complications related to increased waist circumference
Time Frame: 6 months
Abdominal circumference: male: 102cm, female: 88cm
6 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Lilian Oliveira, Guarulhos City Hall

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Anticipated)

August 1, 2021

Primary Completion (Anticipated)

January 1, 2022

Study Completion (Anticipated)

March 1, 2022

Study Registration Dates

First Submitted

December 29, 2020

First Submitted That Met QC Criteria

July 8, 2021

First Posted (Actual)

July 12, 2021

Study Record Updates

Last Update Posted (Actual)

July 15, 2021

Last Update Submitted That Met QC Criteria

July 11, 2021

Last Verified

July 1, 2021

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Diabetes Mellitus, Type 2

3
Subscribe